Avadel Pharmaceuticals Aktie 35154515 / IE00BDGMC594
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
20.11.2025 16:00:05
|
Form 8.3 - Avadel Pharmaceuticals plc
|
Zürcher Kantonalbank (AWDL)
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Ap28
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) (Note 2)
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Ap29
(b) Cash-settled derivative transactions
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
(ii) Exercise
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Ap30
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
(b) Agreements, arrangements or understandings relating to options or derivatives
(c) Attachments
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
Ap31
NOTES ON FORM 8.3
1. See the definition of “connected fund manager” in Rule 2.2 of Part A of the Rules.
2. See the definition of “interest in a relevant security” in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.
3. See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules.
4. See the definition of “dealing” in Rule 2.1 of Part A of the Rules.
5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.
6. See Rule 2.5(d) of Part A of the Rules.
7. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022. Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Category Code: | RET - Avadel Pharmaceuticals plc |
| TIDM: | AWDL |
| LEI Code: | 165GRDQ39W63PHVONY02 |
| Sequence No.: | 408977 |
| EQS News ID: | 2233610 |
| End of Announcement | EQS News Service |
|
|
Nachrichten zu Avadel Pharmaceuticals
|
20.11.25 |
Form 8.3 - Avadel Pharmaceuticals plc (EQS Group) | |
|
20.11.25 |
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc (EQS Group) | |
|
19.11.25 |
Zürcher Kantonalbank: Avadel Pharmaceuticals plc (EQS Group) | |
|
19.11.25 |
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc (EQS Group) | |
|
18.11.25 |
Form 8.3 - Zürcher Kantonalbank: Avadel Pharmaceuticals plc (EQS Group) | |
|
18.11.25 |
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc (EQS Group) | |
|
17.11.25 |
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc (EQS Group) | |
|
14.11.25 |
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc (EQS Group) |
Analysen zu Avadel Pharmaceuticals
Kommt 2025 der grosse KI-Crash? Tim Schäfer über Nvidia, OpenAI & die Parallelen zu 1929
Könnte der aktuelle KI-Boom an den Börsen in einen Crash münden – ähnlich wie 1929 oder zur Dotcom-Blase? 📉💻
In diesem spannenden Gespräch mit Tim Schäfer sprechen wir über Parallelen zum historischen Börsencrash, die massive Überbewertung vieler Tech- und KI-Aktien wie Nvidia, Palantir oder Microsoft – und was das für Langfristanleger bedeutet. Ist der Hype finanziell überhaupt noch tragbar? Wie positionieren sich Insider und Grossinvestoren wie Warren Buffett oder Peter Thiel?
💬 Welche Risiken birgt der aktuelle KI-Hype?
💬 Was sagen Insiderverkäufe und Bewertungen über die Marktlage?
💬 Wie sollte man sich als Privatanleger jetzt aufstellen?
Ein Interview für alle, die sich fragen: Ist das noch Wachstum oder schon Wahnsinn?
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Nach den NVIDIA-Zahlen: SMI letztlich stabil -- DAX schliesst deutlich höher -- US-Börsen gehen schwach aus dem Handel -- Asiens Börsen beenden Handel uneins - Nikkei sehr starkAm Donnerstag verzeichnete der heimische Aktienmarkt marginale Gewinne, während das deutsche Börsenbarometer deutlicher zulegte. Die Wall Street zeigte sich am Donnerstag schwächer. Die Aktienmärkte in Fernost fanden unterdessen keine gemeinsame Richtung.


